Detalhe da pesquisa
1.
Transitioning organizations to post-quantum cryptography.
Nature
; 605(7909): 237-243, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35546191
2.
MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment.
Mol Genet Metab
; 135(2): 143-153, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34417096
3.
Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil.
J Inherit Metab Dis
; 45(2): 340-352, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34910312
4.
Relative Bioavailability Study of Midazolam Intramuscularly Administered with the Needle-Free Auto-Injector ZENEO® in Healthy Adults.
Neurol Ther
; 2024 May 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38806873
5.
In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery.
Mol Pharm
; 8(3): 651-63, 2011 Jun 06.
Artigo
Inglês
| MEDLINE | ID: mdl-21438632
6.
The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.
Arthritis Res Ther
; 23(1): 234, 2021 09 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34488870
7.
Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
PLoS One
; 15(5): e0233032, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32413051
8.
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
J Med Chem
; 61(6): 2246-2265, 2018 03 22.
Artigo
Inglês
| MEDLINE | ID: mdl-29446942
9.
Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes.
Eur J Pharm Sci
; 23(4-5): 385-91, 2004 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-15567292
10.
The perfused everted intestinal segment of rat. 1st communication: absorption kinetics of markers of different permeation mechanisms.
Arzneimittelforschung
; 54(8): 467-73, 2004.
Artigo
Inglês
| MEDLINE | ID: mdl-15460214